149 related articles for article (PubMed ID: 15498877)
1. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat F; Meunier F; Derue G
J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
[No Abstract] [Full Text] [Related]
2. Antibiotic treatment of gram-positive bone and joint infections.
Darley ES; MacGowan AP
J Antimicrob Chemother; 2004 Jun; 53(6):928-35. PubMed ID: 15117932
[TBL] [Abstract][Full Text] [Related]
3. [Moxifloxacin, a novel extended spectrum fluoroquinolone in the treatment of severe infectious inflammatory diseases].
Svetukhin AM; Blatun LA; Ukhin SA
Antibiot Khimioter; 2005; 50(2-3):64-72. PubMed ID: 16308942
[No Abstract] [Full Text] [Related]
4. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.
Nguyen S; Pasquet A; Legout L; Beltrand E; Dubreuil L; Migaud H; Yazdanpanah Y; Senneville E
Clin Microbiol Infect; 2009 Dec; 15(12):1163-9. PubMed ID: 19438638
[TBL] [Abstract][Full Text] [Related]
5. [Novel antibiotics active against Gram-positive bacteria].
Garcia Sánchez JE; Fresnadillo Martínez MJ
Rev Esp Quimioter; 2000 Dec; 13(4):344-51. PubMed ID: 11498700
[No Abstract] [Full Text] [Related]
6. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Hoepelman I
Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Wickman PA; Black JA; Moland ES; Thomson KS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.
El Samad Y; Lanoix JP; Bennis Y; Diouf M; Saroufim C; Brunschweiler B; Rousseau F; Joseph C; Hamdad F; Ait Amer Meziane M; Routier S; Schmit JL
Antimicrob Agents Chemother; 2016 Oct; 60(10):6365-8. PubMed ID: 27458228
[TBL] [Abstract][Full Text] [Related]
9. Empirical antimicrobial therapy for odontogenic infections.
Limeres J; Tomás I; Alvarez M; Diz P
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Sep; 100(3):263-4. PubMed ID: 16122650
[No Abstract] [Full Text] [Related]
10. Controversies in antibiotic choices for odontogenic infections.
Stefanopoulos PK; Kolokotronis AE
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jun; 101(6):697-8. PubMed ID: 16731384
[No Abstract] [Full Text] [Related]
11. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess.
Ott SR; Allewelt M; Lorenz J; Reimnitz P; Lode H;
Infection; 2008 Feb; 36(1):23-30. PubMed ID: 18231720
[TBL] [Abstract][Full Text] [Related]
13. Glycopeptide-resistant Gemella haemolysans from blood.
Reed C; Efstratiou A; Morrison D; Woodford N
Lancet; 1993 Oct; 342(8876):927-8. PubMed ID: 8105186
[No Abstract] [Full Text] [Related]
14. Study on the in-vitro activity of LY333328 against gram-positive cocci.
Mezzatesta ML; Bonfiglio G; De Angelis L; Stefani S; Russo G
J Antimicrob Chemother; 1998 Aug; 42(2):266-8. PubMed ID: 9738850
[No Abstract] [Full Text] [Related]
15. Appropriate oral antibiotics for bone and joint infections based on the susceptibility of clinical Staphylococcus aureus isolates.
Lee CS; Hwang JH; Lee JH; Song SK; Cho JH; Lee JH
Korean J Intern Med; 2015 Mar; 30(2):262-4. PubMed ID: 25750572
[No Abstract] [Full Text] [Related]
16. [Adequate use of teicoplanin in bone and joint infections].
Senneville E; Legout L; Corroyer B; Yazdanpanah Y; Mouton Y
Med Mal Infect; 2004 Jun; 34 Suppl 1():S99-102. PubMed ID: 15676260
[No Abstract] [Full Text] [Related]
17. Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis.
Sezak N; Kuruuzum Z; Cakir N; Yuce A
J Chemother; 2008 Feb; 20(1):58-62. PubMed ID: 18343745
[TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
Grossi O; Caillon J; Arvieux C; Jacqueline C; Bugnon D; Potel G; Hamel A
Antimicrob Agents Chemother; 2007 Sep; 51(9):3401-3. PubMed ID: 17576849
[TBL] [Abstract][Full Text] [Related]
19. [The basic and clinical studies of moxifloxacin: the profile as respiratory quinolones].
Kohno S
Jpn J Antibiot; 2005 Oct; 58(5):431-44. PubMed ID: 16379155
[No Abstract] [Full Text] [Related]
20. Old antimicrobials and Gram-positive cocci through the example of infective endocarditis and bone and joint infections.
Seng P; Amrane S; Million M; Stein A
Int J Antimicrob Agents; 2017 May; 49(5):558-564. PubMed ID: 28365430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
